Edition:
United Kingdom

Carmat SA (ALCAR.PA)

ALCAR.PA on Paris Stock Exchange

23.20EUR
11:41am GMT
Change (% chg)

€0.20 (+0.87%)
Prev Close
€23.00
Open
€23.20
Day's High
€23.25
Day's Low
€22.90
Volume
2,210
Avg. Vol
9,028
52-wk High
€29.50
52-wk Low
€19.50

Latest Key Developments (Source: Significant Developments)

Carmat End-Dec. Cash And Marketable Cash Instruments Of EUR 25.2 Million
Tuesday, 15 Jan 2019 

Jan 15 (Reuters) - CARMAT SA ::PRESENTS POSITIVE INTERIM RESULTS OF THE FIRST PART OF ITS PIVOTAL STUDY.CARMAT HAD CASH AND MARKETABLE CASH INSTRUMENTS OF EUR 25.2 MILLION AT DECEMBER 31, 2018.70% OF PATIENTS IN THIS FIRST COHORT REACHED STUDY'S PRIMARY ENDPOINT.DATA CONFIRM BIOCOMPATIBILITY OF CARMAT PROSTHESIS.COMPANY IS CURRENTLY VALIDATING ADDITIONAL CLINICAL CENTERS IN TWO MORE COUNTRIES IN ORDER TO RAPIDLY COMPLETE ENROLLMENT OF SECOND PATIENT COHORT AND SUBMIT CE MARKING DOSSIER IN EARLY 2020.CARMAT HAD CASH AND MARKETABLE CASH INSTRUMENTS OF EUR 25.2 MILLION AT DECEMBER 31, 2018, VERSUS EUR 44.0 MILLION AT JUNE 30, 2018.CASH BURN OF EUR 19.7 MILLION OVER PERIOD.ACCESS TO AN ADDITIONAL EUR 24.2 MILLION OF FINANCING.  Full Article

Carmat Appoints Pascale D’Arbonneau As Chief Financial Officer
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - CARMAT SA ::CARMAT ANNOUNCES THE APPOINTMENT OF PASCALE D’ARBONNEAU AS CHIEF FINANCIAL OFFICER.  Full Article

Carmat H1 Operating Loss Increases to 19.4 Million Euros
Friday, 28 Sep 2018 

Sept 28 (Reuters) - CARMAT SA ::REPORTS ITS 2018 HALF-YEAR RESULTS AND PROVIDES AN UPDATE ON ITS DEVELOPMENTS.CASH POSITION OF EUR 44.0 MILLION AT JUNE 30, 2018.FINANCIAL RESOURCES WILL ALLOW CONTINUATION OF CLINICAL AND INDUSTRIAL DEVELOPMENTS THROUGH TO GRANTING OF CE MARKING, EXPECTED IN 2019.MORE THAN 50% OF PATIENTS IN PIVOTAL STUDY HAVE NOW BEEN IMPLANTED.OPERATING EXPENSES ARE IN LINE WITH TRANSFORMATION OF CARMAT INTO AN INDUSTRIAL AND COMMERCIAL COMPANY.H1 NET LOSS EUR 18.9 MILLION VERSUS LOSS OF EUR 14.1 MILLION YEAR AGO.H1 OPERATING LOSS EUR 19.4 MILLION VERSUS LOSS OF EUR 14.7 MILLION YEAR AGO.CASH AND MARKETABLE CASH INSTRUMENTS TOTALED EUR 44.0 MILLION AT JUNE 30, 2018, VERSUS EUR 60.7 MILLION AT DECEMBER 31, 2017.CASH BURN OF EUR 20.7 MILLION OVER FIRST HALF OF 2018;.PIVOTAL STUDY CONTINUING IN LINE WITH AIM OF COMPLETING PATIENT ENROLLMENT BY END-2018.CARMAT RECORDED NO REVENUE OVER FIRST HALF OF 2018.  Full Article

Carmat Completes Patient Enrollment In First Part Of PIVOTAL Study
Wednesday, 11 Jul 2018 

July 11 (Reuters) - CARMAT SA ::COMPLETES PATIENT ENROLLMENT IN THE FIRST PART OF THE PIVOTAL STUDY IN LINE WITH THE OBJECTIVE OF OBTAINING CE MARKING IN 2019.STUDY PACE IN LINE WITH OBJECTIVE OF FINALIZING PATIENT ENROLLMENT BEFORE END-2018.CONFIRMS OBJECTIVE TO REACH 20 IMPLANTED PATIENTS BY YEAR-END.IMPLANTATION OF 50% OF THE TOTAL NUMBER OF PLANNED PATIENTS MARKS THE END OF FIRST LEG OF THE PIVOTAL STUDY.  Full Article

Carmat Launches Capital Increase For Initial Amount Of 46 Million Euros
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Carmat ::LAUNCHES A CAPITAL INCREASE WITHOUT SHAREHOLDERS’ PREFERENTIAL SUBSCRIPTION RIGHTS AND WITH A 4-TRADING DAY PRIORITY SUBSCRIPTION PERIOD ON AN IRREDUCIBLE BASIS TO SHAREHOLDERS FOR AN INITIAL AMOUNT OF €46 MILLION.LAUNCHES A CAPITAL INCREASE WITHOUT SHAREHOLDERS’ PREFERENTIAL SUBSCRIPTION RIGHTS AND WITH A 4-TRADING DAY PRIORITY SUBSCRIPTION PERIOD ON AN IRREDUCIBLE BASIS TO SHAREHOLDERS FOR AN INITIAL AMOUNT OF €46 MILLION.‍LAUNCH OF CAPITAL INCREASE WITHOUT SHAREHOLDERS' PREFERENTIAL SUBSCRIPTION RIGHTS FOR AMOUNT OF EUR 46 MILLION​.‍INITIAL AMOUNT MAY BE INCREASED TO MAX OF EUR 52.9 MILLION IN EVENT OF FULL EXERCISE OF INCREASE OPTION​.‍CAPITAL INCREASE TO SECURE FINAL DEVELOPMENT STAGES BEFORE MARKETING OF TOTAL ARTIFICIAL HEART IN EUROPE​.‍MARKETING OF TOTAL ARTIFICIAL HEART IN EUROPE SCHEDULED FOR 2019​.‍EXISTING SHAREHOLDERS ALREADY COMMITTED TO SUBSCRIBE FOR AMOUNT OF EUR 34.5M​.‍MAX NUMBER OF NEW SHARES THAT MAY BE ISSUED IS 4.0 MILLION.‍BNP PARIBAS AND ODDO BHF SCA ACTING AS GLOBAL COORDINATORS, LEAD MANAGERS AND JOINT-BOOKRUNNERS​.‍PORTZAMPARC IS ACTING AS CO-LEAD MANAGER​.‍MAX SUBSCRIPTION PRICE OF NEW SHARES WILL BE EUR 20 PER SHARE​.  Full Article

Carmat: First Implantation In Czech Republic Within Framework Of Pivotal Study International Expansion
Monday, 27 Nov 2017 

Nov 27 (Reuters) - CARMAT ::FIRST IMPLANTATION IN THE CZECH REPUBLIC WITHIN THE FRAMEWORK OF THE PIVOTAL STUDY INTERNATIONAL EXPANSION.‍COMPLETION EXPECTED BY END OF 2018​.  Full Article

Carmat signs a partnership agreement with AddUp
Monday, 13 Nov 2017 

Nov 13 (Reuters) - CARMAT : :CARMAT SIGNS A PARTNERSHIP AGREEMENT WITH ADDUP, THE MICHELIN AND FIVES JOINT VENTURE SPECIALIZED IN 3D PRINTING.‍AIM OF COLLABORATION IS TO STRENGTHEN INDUSTRIAL DEVELOPMENT OF CARMAT HEART AND CONTRIBUTE TO INCREASE CO'S PRODUCTION CAPACITY IN PREPARATION FOR LARGE SCALE PRODUCTION PHASE​.  Full Article

French group Carmat says gets approval to perform implants in Czech Republic
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Carmat Sa ::* Received the approval to perform, within the framework of the PIVOTAL study protocol approved by the ANSM (French national agency for the safety of medicines and health products), implants of its total artificial heart in patients at the Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.  Full Article

Carmat FY net loss widens to 23 million euros
Tuesday, 14 Feb 2017 

Carmat SA : Solid cash position of 31.2 million euros ($33.13 million) at December 31, 2016 . FY net loss of 23 million euros versus loss of 17.6 million euros year ago . FY operating income 262,994 euros versus 14,350 euros year ago .Recorded no revenue in 2016.  Full Article

French and Benelux stocks-Factors to watch on Sept 28

Sept 28 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.